Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Far Infrared Treatment for Alzheimer's Disease

This study is ongoing, but not recruiting participants.
Information provided by:
GAAD Medical Research Institute Inc. Identifier:
First received: January 11, 2008
Last updated: August 14, 2009
Last verified: August 2009
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

Condition Intervention Phase
Alzheimer Disease
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.

Resource links provided by NLM:

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • Management and Cure of Alzheimer's Disease [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Management and Cure of Dementia [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 4
Study Start Date: February 2008
Estimated Study Completion Date: April 2009
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared radiation for 30 to 40 minutes per treatment session.

Detailed Description:

Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal.

Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • People with Alzheimer's disease

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00599469

Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Director: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
  More Information

Responsible Party: Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc. Identifier: NCT00599469     History of Changes
Other Study ID Numbers: GAAD-AD-CTP1 
Study First Received: January 11, 2008
Last Updated: August 14, 2009
Health Authority: Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:
Acute Confusional Senile Dementia
Alzheimer Type Senile Dementia

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on January 17, 2017